Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ATH-063 in Healthy Subjects
NCT05807971 is registered in ClinicalTrials.gov with Athos Therapeutics Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ATH-063 in Healthy Subjects
- Lead sponsor
- Athos Therapeutics Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 6, 2023
- Completion date
- February 8, 2024
- Enrollment
- 76 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
autoimmune diseases, crohn disease, inflammatory bowel diseases, ulcerative colitis